Please login to the form below

Not currently logged in
Email:
Password:

Patent

This page shows the latest Patent news and features for those working in and with pharma, biotech and healthcare.

ViiV takes on Gilead’s PReP dominance with HIV injectable data

ViiV takes on Gilead’s PReP dominance with HIV injectable data

The PrEP market is however due for a shake-up as Truvada’s patents are due to expire next year, allowing generics to be offered for sale, and that could lead

Latest news

More from news
Approximately 69 fully matching, plus 1,605 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    The rationale for this is clear. Not least because of the challenge of patent cliffs for many traditional pharma businesses, the firms that wish to still be around in years to

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Pfizer is coming off ten years of patent expiries, plus a pipeline that hasn’t yielded as many new products as hoped in that period, and that prompted Bourla to implement ... The checklist of retooling initiatives include a deal to merge Pfizer’s

  • Why pharma should invest in the education of doctors Why pharma should invest in the education of doctors

    Given that the patent life of a drug is 10-15 years, and most companies’ pipelines contain multiple drugs in the same therapy area, it makes sense to invest in building

  • Shanks v Unilever? Or David v Goliath? Shanks v Unilever? Or David v Goliath?

    This rule applies to patents applied for pre-2005. After 2005, the employee must also show that it would be ‘just’ for them to receive compensation. ... The patents became worth approximately £24.3m (as calculated by the Hearing Officer in the

More from intelligence
Approximately 3 fully matching, plus 126 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 39 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics